ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol
Latest Information Update: 07 Feb 2023
At a glance
- Drugs Aviptadil (Primary)
- Indications COVID-19 respiratory infection
- Focus Expanded access; Therapeutic Use
- Acronyms SAMICARE
- Sponsors APR Applied Pharma Research; NeuroRX; NRx Pharmaceuticals
Most Recent Events
- 19 Jul 2022 Status changed from recruiting to completed.
- 27 Sep 2021 Results presented in NRx Pharmaceuticals media release.
- 16 Jun 2021 According to a Relief Therapeutics media release, EAP data are being submitted by NRx to the U.S. Food and Drug Administration (FDA) as "real world" evidence in support of the findings from the phase 2b/3 trial.